Dr. Saatheeyavaane Bhuvanendran has been serving as an Assistant Lecturer in Neuroscience at the Brain Research Institute Monash Sunway (BRIMS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, since 2019. She earned her Bachelor of Science degree from AIMST University in 2008 and completed her PhD at Monash University in 2019. Her doctoral research focused on evaluating the neuroprotective effects of natural compounds against Alzheimer’s disease by addressing its multifactorial nature, aiming to develop these compounds into potential treatments or preventive measures for the disease.
Prof. Ammu Kutty Radhakrishnan is a full-time Professor of Immunology at the Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Malaysia. She obtained her PhD in Therapeutic Immunology from the University of Cambridge in March 1994 and was elected as a Fellow of the Royal Society of Biology (RSB), UK, in 2023. Prof. Radhakrishnan joined the International Medical University (IMU) as a lecturer and remained there until February 2019. Her research interests include immunotherapy, immunomodulation, cancer immunology, nutritional immunology, and the health benefits of natural bioactive compounds.
Prof. Radhakrishnan also served as the Associate Dean (Academic and International Affairs) at the School of Medicine, IMU, and was an active member of IMU’s Academic Council, which included senior management personnel and Deans from IMU's international partner medical and dental schools.
Dr. Muhamad Noor Alfarizal Kamarudin is a Lecturer at the Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia. He specialises in cell biology, molecular biology, and tumor biology, with a particular focus on gliomas and glioblastoma.
Dr. Kamarudin’s research aims to unravel the complex mechanisms underlying mesenchymal transition and membranous tube formation that drive glioma motility and resistance to therapy. A significant aspect of his work involves addressing resistance to temozolomide (TMZ) by exploring the synergistic effects of natural products, neuropeptides, and small molecules in regulating key pathways associated with mesenchymal transition and drug resistance.
In addition, Dr. Kamarudin is dedicated to improving early diagnosis of gliomas by identifying novel biomarkers and pathways involved in interactions between glioblastoma cells and the tumor microenvironment. His research aspires to bridge the gap between basic science and clinical application, offering innovative diagnostic and therapeutic strategies to enhance patient outcomes and tackle the challenges posed by this aggressive cancer.
